Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pradaxa Almost Clear Of NICE Hurdle

Nov 01 2011

• By The Pink Sheet Daily

Related Content

Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?

Sep 05 2011

Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval

Sep 30 2011

NICE Demands "Less Biased" Cost Data On Pradaxa For AF

Aug 17 2011

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window